hVIVO (LON:HVO) Shares Up 7.4% - Should You Buy?

hVIVO plc (LON:HVO - Get Free Report)'s stock price shot up 7.4% during trading on Friday . The stock traded as high as GBX 15.75 ($0.20) and last traded at GBX 15.30 ($0.20). 2,298,550 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 3,292,127 shares. The stock had previously closed at GBX 14.25 ($0.18).

hVIVO Price Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market cap of £103.31 million, a PE ratio of 6.02 and a beta of 0.97. The business has a 50 day moving average price of GBX 16.40 and a two-hundred day moving average price of GBX 21.08.

Insider Activity

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total transaction of £520,581.82 ($665,195.27). Insiders own 14.03% of the company's stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.